Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9573 posts found.

eczema_finger

Featured Market Report: Atopic Dermatitis (eczema) Forecast in 17 Major Markets

December 7, 2015 Manufacturing and Production, Research and Development Black Swan, eczema

Featured Market Report: Forecast Report on Atopic Dermatitis (eczema) in 17 Major Markets  Black Swan’s report on Atopic Dermatitis, also …
Feature
Pfizer CEO Ian Read

Five benefits and challenges of the Pfizer/Allergan mega-merger

December 7, 2015 Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Pfizer, acquisitions, mergers, takeovers

Pfizer was extremely keen to get the $160 billion deal done, but what is it getting out of the acquisition, …
Feature
Merck image

Late-stage failure for Merck and Threshold cancer drug

December 7, 2015 Research and Development, Sales and Marketing Merck, Pancreatic cancer, Threshold Pharmaceuticals, evofosfamide, late-stage failure, phase III, sarcoma

Merck and its development partner Threshold Pharmaceuticals say they will not pursue regulatory approval for evofosfamide in advanced soft tissue …
News

Takeda reveals five-year Adcetris survival data

December 6, 2015 Research and Development, Sales and Marketing Hodgkin lymphoma, Takeda, oncology

Takeda UK has announced post-treatment follow up data from the pivotal Phase II study of Adcetris revealing a five-year survival …
News
kyprolis_amgen

Amgen’s Kyprolis doubles Velcade benefit in head-to-head study

December 5, 2015 Research and Development, Sales and Marketing Amgen, Cancer, Kyprolis, Takeda, Velcade, multiple myeloma

Amgen has announced that its multiple myeloma therapy Kyprolis displayed superiority to Takeda’s Velcade in the Phase III ENDEAVOR study …
News
Neusentis

Pfizer to close UK R&D site in surprise move

December 4, 2015 Research and Development, Sales and Marketing Pfizer

Two weeks after its $160 billion buyout of botox-maker Allergan, Pfizer has announced that it is to close a UK …
News
alzheimers-oct-15-portraits-039

Chief scientific officers appointed at dementia Drug Discovery Alliance

December 3, 2015 Medical Communications, Research and Development Alzheimer's Research, dementia, dementia drug discovery alliance

Alzheimer’s Research UK has appointed three chief scientific officers to drive its £30million Drug Discovery Alliance. The Alliance, which unites …
Appointment
Alkermes' Richard Pops

Alkermes aims to take the next biotech step

December 3, 2015 Medical Communications, Research and Development Alkermes

“We think we can be the next Biogen, or a Celgene or a Vertex – we have that much firepower …
Feature

NICE turns down bone disorder drug for NHS

December 3, 2015 Research and Development Alexion, NICE, Strensiq

NICE has published draft guidance as part of its highly specialised technologies programme, not recommending Alexion Pharma’s Strensiq (asfotase alfa) …
News
Propeller Health smart inhaler

GSK collaborates on ‘smart inhaler’ technology for respiratory trials

December 3, 2015 Research and Development COPD, GSK, Propeller, Propeller Health, asthma, clinical trials, ellipta, inhalers, smart drugs, smart inhalers

GSK has entered the ‘smart drug’ industry by partnering with a health technology company to develop a sensor for use …
News
gsk_logo_with_text

GSK gets European approval for asthma treatment Nucala

December 3, 2015 Research and Development GSK, Nucala, asthma

GlaxoSmithKline has received marketing authorisation from the European Commission for Nucala as an add-on treatment for severe refractory eosinophilic asthma …
News
mbeya_microscopy

Janssen in new collaboration to take on TB

December 3, 2015 Research and Development FIND, Janssen, antibiotic resistance, tuberculosis

Janssen has announced a new collaboration with the non-profit organisation FIND to step-up the fight against the public health threat …
News
zafgen_logo

Second patient dies in Zafgen obesity trial

December 3, 2015 Research and Development

Zafgen has announced the death of a second participant in a Phase III clinical trial of its obesity drug beloranib …
News
Victoza

Novo Nordisk buys Xoma diabetes program and scores trial successes

December 2, 2015 Research and Development, Sales and Marketing Novo Nordisk, Ryzodeg, SGLT2 inhibitors, Victoza, Xoma, diabetes

Novo Nordisk has announced its purchase of a type 2 diabetes diabetes program in a deal with biotech firm Xoma …
News
EU flags

Horizon receives European go-ahead for Ravicti

December 2, 2015 Research and Development, Sales and Marketing Horizon Pharma, Ravicti, horizon, orphan drug, rare disease, urea cycle disorders

The European Commission has approved Ravicti for rare urea cycle disorders.  Ravicti, (glycerol phenylbutyrate), is an oral liquid developed by Horizon …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025